{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:17:52Z","timestamp":1722903472230},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","sleep.theclinics.com","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine Clinics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jsmc.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:28:31Z","timestamp":1717590511000},"page":"473-483","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Disease-modifying Therapies on Respiratory Function in People with Neuromuscular Disorders"],"prefix":"10.1016","volume":"19","author":[{"given":"Lena","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib1","first-page":"121","article-title":"Improvement of survival in duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib2","first-page":"117","article-title":"Survival in Duchenne muscular dystrophy","volume":"31","author":"Rall","year":"2012","journal-title":"Acta Myol"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib5","doi-asserted-by":"crossref","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","article-title":"Survival of patients with spinal muscular atrophy type 1","volume":"131","author":"Gregoretti","year":"2013","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.jsmc.2024.04.004_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jsmc.2024.04.004_bib7","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/ppul.24455","article-title":"Relationship between respiratory function and need for NIV in childhood SMA","volume":"54","author":"Kapur","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib9","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","article-title":"Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study","volume":"96","author":"Trucco","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jsmc.2024.04.004_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.sleep.2019.12.004","article-title":"Polysomnography findings in pediatric spinal muscular atrophy types 1\u20133","volume":"68","author":"Chacko","year":"2020","journal-title":"Sleep Med"},{"key":"10.1016\/j.jsmc.2024.04.004_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.sleep.2023.09.019","article-title":"Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy","volume":"111","author":"Chiang","year":"2023","journal-title":"Sleep Med"},{"issue":"15","key":"10.1016\/j.jsmc.2024.04.004_bib12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"18","key":"10.1016\/j.jsmc.2024.04.004_bib13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jsmc.2024.04.004_bib15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jsmc.2024.04.004_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jsmc.2024.04.004_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib18","first-page":"135","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.jsmc.2024.04.004_bib19","first-page":"54","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience","volume":"39","author":"Chen","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"9","key":"10.1016\/j.jsmc.2024.04.004_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ppul.26173","article-title":"Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen","volume":"58","author":"Xiao","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jsmc.2024.04.004_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1\u20133","volume":"77","author":"Chacko","year":"2022","journal-title":"Thorax"},{"issue":"14","key":"10.1016\/j.jsmc.2024.04.004_bib23","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jsmc.2024.04.004_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/children9081207","article-title":"Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies","volume":"9","author":"Panagiotou","year":"2022","journal-title":"Children"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Euro J of Neurology"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib27","doi-asserted-by":"crossref","first-page":"e15310","DOI":"10.1111\/ped.15310","article-title":"The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy","volume":"64","author":"Hepkaya","year":"2022","journal-title":"Pediatr Int"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib28","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Communications"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.jsmc.2024.04.004_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.nmd.2023.04.007","article-title":"Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience","volume":"33","author":"Gonski","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jsmc.2024.04.004_bib33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpn.2021.02.007","article-title":"Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy \u2013 a single-center retrospective study","volume":"31","author":"Heitschmidt","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","article-title":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","volume":"32","author":"Fainmesser","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jsmc.2024.04.004_bib35","doi-asserted-by":"crossref","first-page":"650532","DOI":"10.3389\/fneur.2021.650532","article-title":"Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"issue":"18","key":"10.1016\/j.jsmc.2024.04.004_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.jsmc.2024.04.004_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.jsmc.2024.04.004_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jsmc.2024.04.004_bib41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jsmc.2024.04.004_bib42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jsmc.2024.04.004_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D\u2019Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib44","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ppul.26285","article-title":"A\u00a0breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy","volume":"58","author":"AlNaimi","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jsmc.2024.04.004_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.sleep.2022.11.006","article-title":"Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec","volume":"101","author":"Leon-Astudillo","year":"2023","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.jsmc.2024.04.004_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase i ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"JND"},{"issue":"10","key":"10.1016\/j.jsmc.2024.04.004_bib48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jsmc.2024.04.004_bib50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib52","first-page":"2531","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27755","article-title":"Risdiplam for the treatment of adults with spinal muscular atrophy: experience of the Northern Ireland neuromuscular service","volume":"67","author":"McCluskey","year":"2023","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy","volume":"67","author":"\u00d1ungo Garz\u00f3n","year":"2023","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.jsmc.2024.04.004_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ppul.23172","article-title":"Characterization of pulmonary function in duchenne muscular dystrophy","volume":"50","author":"Mayer","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","article-title":"Deflazacort treatment of Duchenne muscular dystrophy","volume":"138","author":"Biggar","year":"2001","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"issue":"10101","key":"10.1016\/j.jsmc.2024.04.004_bib59","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jsmc.2024.04.004_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2217\/cer-2021-0196","article-title":"Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients","volume":"11","author":"McDonald","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib61","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12891-021-04700-z","article-title":"Long term treatment with ataluren\u2014the Swedish experience","volume":"22","author":"Michael","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.jsmc.2024.04.004_bib64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of long-term ambulatory function in patients with duchenne muscular dystrophy treated with eteplirsen and matched natural history controls","volume":"8","author":"Mendell","year":"2021","journal-title":"JND"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JND-170272","article-title":"Long-term pulmonary function in duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history","volume":"5","author":"Kinane","year":"2018","journal-title":"JND"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A\u00a0combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"JND"},{"issue":"2","key":"10.1016\/j.jsmc.2024.04.004_bib67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/JND-180351","article-title":"Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with duchenne muscular dystrophy","volume":"6","author":"Khan","year":"2019","journal-title":"JND"},{"issue":"3","key":"10.1016\/j.jsmc.2024.04.004_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mus.27662","article-title":"Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy","volume":"66","author":"Iff","year":"2022","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jsmc.2024.04.004_bib69","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"JND"},{"issue":"21","key":"10.1016\/j.jsmc.2024.04.004_bib70","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jsmc.2024.04.004_bib71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Therapeut"},{"issue":"8","key":"10.1016\/j.jsmc.2024.04.004_bib72","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.jsmc.2024.04.004_bib73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and safety of viltolarsen in boys with duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study","volume":"10","author":"Clemens","year":"2023","journal-title":"JND"},{"year":"2021","series-title":"Amondys 45 (casimersen) injection, for intravenous use","key":"10.1016\/j.jsmc.2024.04.004_bib74"},{"issue":"9","key":"10.1016\/j.jsmc.2024.04.004_bib76","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"}],"container-title":["Sleep Medicine Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X24000420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X24000420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:26:15Z","timestamp":1722893175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556407X24000420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1556407X24000420"],"URL":"https:\/\/doi.org\/10.1016\/j.jsmc.2024.04.004","relation":{},"ISSN":["1556-407X"],"issn-type":[{"type":"print","value":"1556-407X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Disease-modifying Therapies on Respiratory Function in People with Neuromuscular Disorders","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsmc.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}